<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806933</url>
  </required_header>
  <id_info>
    <org_study_id>M602011015</org_study_id>
    <secondary_id>2018-002743-28</secondary_id>
    <nct_id>NCT03806933</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Multicenter Study to Investigate the Safety and Duration of Effect of Different NT 201 Dose Groups Following the Treatment of Glabellar Frown Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety and duration of effect following
      different doses of Botulinum Toxin A (NT 201) in the treatment of glabellar frown lines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized, double-blind, multi-Center clinical study consists of a two
      stage experimental main period comparing different dose groups, followed by an optional
      open-label extension (20 Units follow-up treatment).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of effect as defined by time between treatment and relapse to baseline status</measure>
    <time_frame>From time of treatment to up to 360 days</time_frame>
    <description>Effect is defined as improvement at maximum frown as assessed by the investigator on the Facial Wrinkle Scale (FWS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of effect whereby effect is defined by a score of none (0) or mild (1) at maximum frown as assessed by the investigator according to FWS</measure>
    <time_frame>From time of treatment to up to 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of effect whereby effect is defined as 2-point improvement from baseline at maximum frown as assessed by the investigator according to FWS</measure>
    <time_frame>From time of treatment to up to 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects rated as none (0) or mild (1) at maximum frown by investigator's rating on FWS at Day 180</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects rated as none (0) or mild (1) at maximum frown by subject's rating on FWS at Day 180</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects rated as at least 1-point improvement compared to baseline at maximum frown by investigator's rating on FWS at Day 180</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects rated as at least 1-point improvement compared to baseline at maximum frown by subject's rating on FWS Subject at Day 180</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Moderate to Severe Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>NT 201 Dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1 and 2. Intramuscular injection into the glabellar area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT 201 Dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1. Intramuscular injection into the glabellar area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT 201 Dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1. Intramuscular injection into the glabellar area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT 201 Dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 2. Intramuscular injection into the glabellar area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT 201 Dose group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label Extension Period. Intramuscular injection into the glabellar area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT 201</intervention_name>
    <description>Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).</description>
    <arm_group_label>NT 201 Dose group 1</arm_group_label>
    <arm_group_label>NT 201 Dose group 2</arm_group_label>
    <arm_group_label>NT 201 Dose group 3</arm_group_label>
    <arm_group_label>NT 201 Dose group 4</arm_group_label>
    <arm_group_label>NT 201 Dose group 5</arm_group_label>
    <other_name>IncobotulinumtoxinA</other_name>
    <other_name>Xeomin</other_name>
    <other_name>Botulinum toxin type A (150 kiloDalton), free from complexing proteins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject 18 years or over.

          -  Moderate (score = 2) to severe (score =3) GFL at maximum frown as assessed by
             investigator on the 4-point FWS.

          -  Moderate (score = 2) to severe (score =3) GFL at maximum frown as assessed by subject
             on the 4-point FWS.

        Exclusion Criteria:

          -  Previous treatment with Botulinum neurotoxin (BoNT) of any serotype in the facial area
             within the last 12 months before injection.

          -  Previous treatment with any facial cosmetic procedure (e.g., chemical peeling, photo
             rejuvenation, mesotherapy, photodynamic therapy, laser treatment, tattooing of
             eyebrows) in the glabellar area within the last 12 months before injection.

          -  Previous treatment with any biodegradable filler in the glabellar area within the last
             12 months before injection.

          -  Inability to substantially reduce GFL by physically spreading them apart as assessed
             by the investigator.

          -  Excessively thick sebaceous skin or hypertrophic muscles in the upper third part of
             the face.

          -  Any surgery or scars in the glabellar area.

          -  Marked facial asymmetry.

          -  Eyelid ptosis.

          -  Marked brow ptosis and/or dermatochalasis.

          -  Ongoing severe or unstable medical conditions, e.g., systemic infection, or pulmonary
             disease, at the discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Testing of Beverly Hills, Merz Investigational Site #0010395</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Inc., Merz Investigational Site #0010435</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cosmetic Laser Dermatology, Merz Investigational Site #0010321</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Maas Clinics, Merz Investigational Site #0010338</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center, Merz Investigational Site #0010097</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatpraxis für Dermatologie und Ästhetische Medizin, Merz Investigational Site #0490306</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Hamburg, Fachrichtung Kosmetik und Körperpflege, Merz Investigational Site #0490095</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologische Gemeinschaftspraxis Dr. Prager und Partner, Merz Investigational Site #0490345</name>
      <address>
        <city>Hamburg</city>
        <zip>22609</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin &amp; Laser Center, Merz Investigational Site #0490362</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

